retatrutide mechanism gip glp-1 glucagon triple agonist peptide for weight loss and fat burning Retatrutide—A Game Changer in Obesity

AF, atrial fibrillation

Dawkins and Pratley note that while studies show people with obesity and type 2 diabetes experience significant weight loss on a GLP-1 agonist or dual agonist, people with type 2 diabetes experience slightly less weight loss compared with those with overweight and obesity without type 2 diabetes.1-3 Counseling Tips for RDs Despite the success of these classes of weight management medications, patients can receive anywhere from a little to a lot of information on how to optimize their use since a wide variety of clinicians, from primary care providers to obesity medicine experts, prescribe them

Reduction of Heart Failure About half of people with heart failure have preserved ejection fraction (HFpEF), so rather than diminished pump function it is the impaired ability for the heart to relax and fill (diastolic dysfunction) that accounts for their symptoms

DPP-4i = dipeptidyl peptidase-4 inhibitor

HbA1c is crucial for assessing diabetes severity and HF development risk [82]

Receptor selectivity or crosstalk studies: Tirzepatide is a better tool for dissecting GIP/GLP-1 crosstalk